The latest price target for Trevi Therapeutics (NASDAQ:TRVI) was reported by D. Boral Capital on January 8, 2025. The analyst firm set a price target for $21.00 expecting TRVI to rise to within 12 months (a possible 366.67% upside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Trevi Therapeutics (NASDAQ:TRVI) was provided by D. Boral Capital, and Trevi Therapeutics maintained their buy rating.

There is no last upgrade for Trevi Therapeutics

There is no last downgrade for Trevi Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trevi Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trevi Therapeutics was filed on January 8, 2025 so you should expect the next rating to be made available sometime around January 8, 2026.

While ratings are subjective and will change, the latest Trevi Therapeutics (TRVI) rating was a maintained with a price target of $21.00 to $21.00. The current price Trevi Therapeutics (TRVI) is trading at is $4.50, which is out of the analyst’s predicted range.